Last updated on April 19, 2014 at 13:20 EDT

MGB Biopharma to Present at Bio-Europe 2013

November 4, 2013

GLASGOW, Scotland, November 4, 2013 /PRNewswire/ –

MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives,
announces today that CEO Dr Miroslav Ravic will present at Bio-Europe 2013
[http://www.ebdgroup.com/bioeurope/index.php ] in Vienna, Austria (4-6 November). Details
of the presentation on 6 November are listed below.

Dr Ravic will highlight MGB Biopharma’s recent rapid progress in developing a truly
novel class of anti-infectives. The Company’s lead candidate MGB-BP-3 is an antibacterial
active against a broad range of multi-resistant Gram-positive pathogens. The Company has
completed preclinical development of an oral formulation that is ready to enter the clinic
for Clostridium difficile. In addition, MGB Biopharma is developing an intravenous
formulation of MGB-BP-3 for hospital acquired Gram-positive infections and this is
expected to be IND-ready by the end of 2014.

MGB-based anti-infectives have the potential to deliver significant advantages over
current approaches including broad, bactericidal activity against multi-resistant
Gram-positive and Gram-negative pathogens. The platform also promises to deliver compounds
that are active against certain viruses, fungi and parasites. MGB’s anti-infectives are
based on its minor groove binder (MGB) technology platform.

Dr Miroslav Ravic, CEO of MGB Biopharma, said: “Antimicrobial resistance is clearly a
major global public health concern. Yet, the lack of truly novel agents, even among late
stage candidates, means that, as an industry, we are ill equipped to tackle this problem.
We believe that MGB’s truly novel minor groove binder technology platform, could for the
first time in a more than a decade, provide novel agents that offer a real breakthrough in
addressing antimicrobial resistance. In particular our lead candidate MGB-BP-3 has shown
significant antibacterial activity against a range of Gram positive pathogens and we
expect to announce further progress with our on-going programs with MGB-BP-3 in the coming

Details of the presentation are as follow:

Title: Infectious Diseases Presentation stream: MGB Biopharma Limited

Time: 10.15am

Location: Level 1, Schubert 4

Venue: Messe Wien Exhibition and Congress Center

About MGB Biopharma

MGB Biopharma is developing a truly novel class of anti-infectives. MGB’s lead
candidate, MGB-BP-3, is a broad spectrum antibacterial which is active against key
multi-resistant Gram positive pathogens. The Company has developed an oral formulation of
MGB-BP-3 for Clostridium difficile that is ready to enter the clinic, while an IV
formulation for a range of Gram positive infections is in late-stage preclinical

MGB’s anti-infective drug development capabilities are driven by its broad
anti-infective platform, which has the potential to generate truly novel compounds active
against other infectious diseases such as Gram negative pathogens as well parasites and

MGB’s anti-infectives are based on minor groove binders (MGBs). Minor groove binders
have a new mode of action that offers significant advantages over existing anti-infectives
, such as being more bactericidal and active against a broad range of drug-resistant

MGB has close links with the University of Strathclyde, with exclusive worldwide
licence rights to Strathclyde’s MGB patents for all fields expect anticancer. The Company
intends to work with partners to fully capitalize on the multiple value creating
opportunities offered by its broad and novel anti-infectives platform.

The Company was founded in 2010 and is headquartered in Glasgow, Scotland. It is
backed by Scotland’s investors including Archangel Informal Investment, Barwell,
TriCapital and Scottish Co-Investment Fund. For more information please visit


        For further information, please contact:

        MGB Biopharma
        Gavin Clark, Chief Business Officer

        Citigate Dewe Rogerson
        David Dible/Sita Shah

SOURCE MGB Biopharma

Source: PR Newswire